Clinical trial Destiny - Breast06
Phase III Study of Trastuzumab Deruxtecan versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive, Breast Cancer Patients whose Disease has Progressed On Endocrine Therapy in the Metastatic Setting
Cancers | |
---|---|
Organ | Breast |
Trial status | Trial closed for recruitment |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 3 |
Academic trial | Non |
Sponsor | AstraZeneca |
EudraCT Identifier | 2019-004493-26 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04494425 |
Last update |